253 related articles for article (PubMed ID: 38067120)
21. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
22. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.
Ma Y; McCarty SK; Kapuriya NP; Brendel VJ; Wang C; Zhang X; Jarjoura D; Saji M; Chen CS; Ringel MD
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1314-22. PubMed ID: 23709653
[TBL] [Abstract][Full Text] [Related]
23. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
[TBL] [Abstract][Full Text] [Related]
24. p21-Activated kinases as promising therapeutic targets in hematological malignancies.
Wu A; Jiang X
Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424
[TBL] [Abstract][Full Text] [Related]
25. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
26. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
McCarty SK; Saji M; Zhang X; Jarjoura D; Fusco A; Vasko VV; Ringel MD
Endocr Relat Cancer; 2010 Dec; 17(4):989-99. PubMed ID: 20817787
[TBL] [Abstract][Full Text] [Related]
27. Pak protein kinases and their role in cancer.
Dummler B; Ohshiro K; Kumar R; Field J
Cancer Metastasis Rev; 2009 Jun; 28(1-2):51-63. PubMed ID: 19165420
[TBL] [Abstract][Full Text] [Related]
28. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer.
Yeo D; Phillips P; Baldwin GS; He H; Nikfarjam M
Int J Cancer; 2017 May; 140(9):2101-2111. PubMed ID: 28109008
[TBL] [Abstract][Full Text] [Related]
30. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
31. PAK signaling in oncogenesis.
Molli PR; Li DQ; Murray BW; Rayala SK; Kumar R
Oncogene; 2009 Jul; 28(28):2545-55. PubMed ID: 19465939
[TBL] [Abstract][Full Text] [Related]
32. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma.
Ma W; Wang Y; Zhang R; Yang F; Zhang D; Huang M; Zhang L; Dorsey JF; Binder ZA; O'Rourke DM; Fraietta JA; Gong Y; Fan Y
Nat Cancer; 2021 Jan; 2(1):83-97. PubMed ID: 35121889
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
34. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Liu Y; Wang S; Dong QZ; Jiang GY; Han Y; Wang L; Wang EH
Med Oncol; 2016 Mar; 33(3):22. PubMed ID: 26820570
[TBL] [Abstract][Full Text] [Related]
35. Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines.
Porcu G; Parsons AB; Di Giandomenico D; Lucisano G; Mosca MG; Boone C; Ragnini-Wilson A
Mol Cancer; 2013 Aug; 12(1):88. PubMed ID: 23915247
[TBL] [Abstract][Full Text] [Related]
36. p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
Chow HY; Stepanova D; Koch J; Chernoff J
PLoS One; 2010 Nov; 5(11):e13791. PubMed ID: 21072183
[TBL] [Abstract][Full Text] [Related]
37. Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases.
Kumar R; Paul AM; Amjesh R; George B; Pillai MR
Cancer Metastasis Rev; 2020 Sep; 39(3):583-601. PubMed ID: 32820388
[TBL] [Abstract][Full Text] [Related]
38. Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
Thillai K; Lam H; Sarker D; Wells CM
Oncotarget; 2017 Feb; 8(8):14173-14191. PubMed ID: 27845911
[TBL] [Abstract][Full Text] [Related]
39. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
[TBL] [Abstract][Full Text] [Related]
40. Novel therapeutic targets for pancreatic cancer.
Tang SC; Chen YC
World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
